SCHEMBL7711250

SCHEMBL7711250

CC1Oc2ccc(C(Cc3cccc(F)c3)NC(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.46
NPSR1 Q6W5P4 6/20 0.46
HPGD P15428 5/20 0.46
HTT P42858 5/20 0.46
HSD17B10 Q99714 3/20 0.46
JAK2 O60674 3/20 0.46
TP53 P04637 2/20 0.46
MAPK1 P28482 1/20 0.46
ATM Q13315 1/20 0.46
CTSS P25774 3/20 0.45
CTSK P43235 3/20 0.45
TSHR P16473 6/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
LMNA P02545 6/20 0.42
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
SCN9A Q15858 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708356 0.91 CTSS (0.41) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7704912 0.91 ALDH1A1 (0.45) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7711362 0.90 PTPRB (0.40) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7704904 0.90 CTSL (0.45) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7704877 0.90 CACNA1B (0.40) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7711187 0.87 SIRT2 (0.38) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7711369 0.87 ALDH1A1 (0.37) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7708193 0.86 ALDH1A1 (0.38) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7711460 0.86 ALDH1A1 (0.34) ALDH1A1NPSR1HPGDHTTHSD17B10
SCHEMBL7710869 0.86 CTSS (0.42) ALDH1A1NPSR1HPGDHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed